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Background. Acute lymphoblastic leukemia type B (B-ALL) is a neoplastic disorder with high mortality rates. The aim of this study
was to validate the expression profile of 45 genes associated with signaling pathways involved in leukemia and to evaluate their
association with the prognosis of B-ALL. Methods. 219 samples of peripheral blood mononuclear cells obtained from 73 B-ALL
patients were studied at diagnosis, four, and eight weeks after starting treatment. Gene expression was analyzed by quantitative real-
time polymerase chain reaction. Results. Normalized delta Cq values of 23 genes showed differences between B-ALL and controls
at diagnosis time (𝑃 values < 0.05). There were significant associations between B-ALL patients relapse/death and the expression
levels of IL2RA, SORT1, DEFA1, and FLT3 genes at least in one of the times evaluated (𝑃 values < 0.05 and odds ratio ranges: 3.73–
27). The association between FLT3 deregulation and relapse/death was a constant in the times studied and their overexpression
significantly increased the odds of relapse/death in a range of 3.73 and 6.05 among study population (𝑃 values < 0.05). Conclusions.
Overexpression of FLT3 and DEFA1 genes retained independent prognostic significance for B-ALL outcome, reflected as increased
risks of relapse/death among the study population.
1. Background
Acute lymphoblastic leukemia (ALL) is a neoplastic disorder
of lymphoid progenitor cells characterized by diverse cyto-
genetic and molecular abnormalities with peaks of preva-
lence for 2–5-year-old patients and those older than 50
[1]. Treatment strategies using risk-adapted chemotherapy
cure more than 80% of childhood cases, but around 20
to 30% relapse developing serious complications including
death [2, 3]. The ALL cases originated from B lymphocyte
progenitors represent 85% of childhood and 75% of adult
cases, respectively [2, 4]. In Mexico, leukemia mortality
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represents the second leading cause of death in childhood and
adolescence and the 18th in patients during the productive
age (15 to 64 years old) [5, 6].
Common cytogenetic subtypes abnormalities such as
TEL-AML1 (ETV6-RUNX1)/t(12;21), BCR-ABL (BCR-
ABL1)/t(9;22), MLL rearrangements/t(11q23), E2A-PBX1
(TCF3-PBX1)/t(1;19), MYC-IGH/[t(8;14), t(2;8) or t(8;22)],
andhyperdiploidy/(50 chromosomes) are typically associated
with ALL prognosis and together with age, white blood cell
(WBC) count, leukemic cell immunophenotype, and time
to respond to therapy define the risk stratification group [7].
However, major prognostic abnormalities in chromosome
number or structure are absent in approximately 10–30% of
ALL patients, and in a significant number of cases the pre-
diction is not successful [8–10]. Deregulated gene expression
of several key cellular pathways has been suggested as a
useful tool to refine prognosis and identify novel therapeutic
targets in ALL [11]. Though there are many studies of
gene expression based on microarray technologies that
suggest candidate genes for the prognosis or outcome for
ALL patients [11–15], to date all the validation studies have
focused on a small number of genes or in strategies tailored
to specific disease subgroups.
Attending the need to improve relapse prediction, the aim
of this study was the longitudinal validation of a comprehen-
sive gene expression profile of 45 candidate genes involved in
key cell signaling pathways and to determine whether their
expression was associated with relapse in a group of Mexican
B-ALL patients. In this panel, genes and pathways previously
reported as altered by expression or copy number variations
(CNV), known targets of sequence mutations in ALL, genes
commonly mutated in other cancers, and ALL nonrelated
genes involved in key signaling pathways were studied [16–
18].
2. Methods
2.1. Patients and Samples. The patients included in this study
were newly diagnosed with ALL by cytological examination,
peripheral blood, or bone marrow aspirates analysis, and the
B lineage lymphocytic precursor was determined by flow
cytometry (see Table 1 for the B-ALL cases characteristics).
All patients (adults and children’s parents or guardians)
provided written informed consent for participation and
were treated according to the standard protocols of the
Hematology Service of the Hospital Universitario “Dr. Jose´ E.
Gonza´lez”, School of Medicine of the Universidad Autonoma
de Nuevo Leon (UANL), Mexico. Patients received an induc-
tion to remission regimen with 3 or 4 drugs, based on
previously published protocols [19, 20]. Children with B-
ALL were stratified into standard and high risk groups
according to the accepted criteria (see Additional Table 1
for treatment details in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/828145) [8, 21]. The
study followed the criteria of the Declaration of Helsinki and
was approved by the Institutional Ethics Committee with the
reference number BI05-006.
A total of 73 patients provided peripheral blood at the
time of diagnosis and at one and two months after the B-ALL
Table 1: General characteristics of 73 B-ALL patients.
Characteristic Number ofcases (%) Mean (range)
Sex
Male 44 (60.3) —
Female 29 (39.7)
Age
0 to 18 55 (75.3) 7.9 (1–18)
Older than 19 18 (24.7) 28.7 (19–44)
MIC classification
Early precursor B 2 (2.7)
—ALL common 22 (30.1)
ALL pre-B 24 (32.9)
ALL B 25 (34.3)
Diagnosis risk
High 39 (53.4) —
Regular 34 (46.6)
White-cell count (/mm3)
<10,000 49 (67.1) 3,676.4 (6.67–9.1 × 103)
10,000–49,999 16 (21.9) 22,025 (1 × 104–4.7 × 104)
50,000–100,000 2 (2.8) 78,755 (7.8 × 104–7.9 × 104)
>100,000 6 (8.2) 212,150 (1 × 105–3.2 × 105)
Percentage of leukemic
blasts cells at B-ALL
diagnosis
31 (42.5) 75.4 (17.5–95.0)
diagnosis. All the samples were collected between September
2005 and February 2008 andwere followed for 3 years. A total
of 225 samples were used in the study, including 219 leukemic
(73 at diagnosis, 73 at first, and 73 at secondmonth, resp.) and
6 healthy peripheral blood controls. A complete blood count
(CBC) was made for each patient and a molecular screening
of BCR-ABL translocation was assessed by quantitative real-
time polymerase chain reaction (qRT-PCR) according to
standardized protocols of the Unidad de Diagno´stico Molec-
ular del Departamento de Bioquimica y Medicina Molecular
de la Facultad de Medicina de la UANL, Mexico.
2.2. RNA Isolation and cDNA Synthesis. Mononuclear cells
were purified by Histopaque-1077 (Sigma-Aldrich, St. Louis,
MO) and preserved in RNAlater Solution (Life Technologies,
Carlsbad, CA) at −20∘C. Total RNA was extracted from the
mononuclear cells using Qiagen RNeasy Mini Kit (Qiagen,
West Sussex, UK) according to the manufacturer’s protocol.
RNA concentration and its quality were determined by
measurement of the optical density at 260 nm and relation
260/280, respectively, using NanoDrop Spectrophotometer
(NanoDrop Technologies, Wilmington, DE). Samples with a
relation of 260/280 > 1.8 were used in the next steps of the
analysis. RNA was stored at −80∘C until use. cDNA was syn-
thesized from 1.0 𝜇g of total RNA, in a final volume of 20𝜇L,
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using SuperScriptTM III First-Strand Synthesis SuperMix
and random hexamers (Invitrogen, Carlsbad, CA) according
to themanufacturer’s protocol.Thefinal cDNAconcentration
was measured and the samples were stored at −20∘C.
2.3. Gene Selection and Primer Design. A total of 45 genes
representing key signaling pathways and functional pro-
cesses were selected for this study (Additional Table 2);
32 of them had previously been related to ALL (a list of
references of these studies may be consulted in Additional
Table 2). In addition, two reference genes RPL13A andHPRT1
were selected as internal quantitative controls. Gene specific
primers for real-time qPCR assay were selected from the
Primer Bank database (http://pga.mgh.harvard.edu/primer-
bank/) and provided by Invitrogen. The primer sequences
and product sizes for CCR5, IL10, WNT5, FZD3, CTNNB1,
GSK3B, JNK, SOS1, BCL11A, JAK2, STAT5, JUN, BCL2A1,
IL2RA, CCND2, RXRA, PDE4D, STAT1, CD10, CREB1, FOS,
CYLD, RAPGEF2, SORT1, HK2, S100A8, DOCK10, MYH9,
PAPD5, CD2, CD3D, CD8A, PBX1, FAT, NKG2-D, HOXA9,
CD44, TNFRSF7, NOTCH1, DEFA1, OPAL1, CASP8AP2,
PAX5, FLT3, MYC, RPL13A, and HPRT1 are listed in the
Additional Table 2. The efficiency and specificity of each
primer set were confirmed with standard curves and melting
profile evaluation, and efficiency of amplification relative to
reference genes was confirmed by standard curve; all the
procedureswere carried out following the respective standard
guidelines reported previously [22].
2.4. Quantitative Real-Time PCR. The qRT-PCR analyses
were performed with an ABI 7900 high throughput real-time
PCR System (Applied Biosystems, Foster City, CA) in a total
volume of 20 𝜇L containing 15 ng of cDNA, 1X SYBR Green
PCR Master Mix (Applied Biosystems Inc.) and 300 nM of
each primer. All samples were analyzed in duplicate, and
melting curve analysis was done to confirm the specificity
of amplification and lack of primer dimers. The thermal
cycle program consisted of an initial denaturation at 95∘C
for 10min, followed by an amplification step for 40 cycles of
15 s at 95∘C and 1min at 60∘C. Each experiment included two
nontemplate controls to detect any template contamination.
The 2−ΔΔCt equation was applied to calculate the relative
expression of B-ALL samples [23].Themean of quantification
cycle (Cq) of normal blood samples was used as a calibrator.
2.5. Statistical Analysis. Simple comparisons of normalized
ΔCq values (square of ΔCq values) between B-ALL cases
and healthy controls were determined by Student’s 𝑡-test
or Mann-Whitney Rank Sum Test. To evaluate the B-ALL
diagnosis capacity of selected genes and/or cutoff values
of the gene expression, a receiver operating characteristic
curve (ROC) analysis was performed. Differences in the
gene expression levels between times were evaluated by
repeated measures paired 𝑡 test or Wilcoxon Signed Rank
Test. Log-Rank Survival Analysis was performed to evaluate
differences between survival curves (constructed using event-
free survival (EFS) and relapse-free survival (RFS) ALL
cases) considering the cutoff values calculated for the genes
differentially expressed between times (ROC analysis). In this
evaluation the event was defined by relapse or death and the
cases that did not experience the event were classified as EFS.
EFS was calculated from the date of diagnosis to the last
follow-up or the development of an unfavorable event during
the 3 years of monitoring.The odds ratio analysis was carried
out for groups with positive differences between survival
curves; the case grouping was based on the gene expression
level for the gene of interest above or equal/below their cutoff
calculated previously. The evaluation of the usefulness of
IL2RA, SORT1, FLT3, and DEFA1 expression as independent
predictors of B-ALL outcome was performed by multivariate
logistic regression using EFS/RFS as dependent variable.
Finally, a Spearman Rank Order Correlation analysis was
used to test the correlation between expression levels of the
genes associated with survival and clinical data such as WBC
count, percentages of leukemic blasts, and/or diagnosis age.
Along the statistical tests, 𝑃 values lower than 0.05 were
considered statistically significant. Statistical analysis was
performed in the Sigma Plot v.11 and GraphPad Prim v5.03
software, respectively.
3. Results
The study group included 73 B-ALL cases; 75.3% (55) were
children (age range: 0 to 18 years) and 24.7% (18) adults
(age range: 19 to 44 years). Morphologic, immunologic,
and cytogenetic (MIC) working classification grouped 90%
of the cases in the three most common B-ALL diagnoses:
ALL common, Pre-B-ALL, and B-ALL, respectively (Table 1).
39 cases (53.4%) were classified as high risk at diagnosis
and 34 (46.6%) as standard risk. The presence of BCR-ABL
rearrangement was found in three cases (4.1%); one of them
relapsed during the 3 years of the study. Of the 73 B-ALL
patients included 19 (26%) relapsed and 4 (5.5%) died during
follow-up.
Additional Table 3 shows the normalized ΔCq values
obtained for the study groups. Out of 45 analyzed gene
expressions, normalized ΔCq values of 23 genes at diag-
nosis, 23 at one month, and 28 at second month after
starting treatment showed statistical differences between B-
ALL cases and healthy controls (𝑃 values < 0.05). Differences
found in 19 genes at diagnosis (IL10, WNT5A, FZD3, JNK,
SOS1, JUN, OPAL1, MYC, CCND2, PDE4D, CREB1, FOS,
CYLD, RAPGEF2, SORT1, DOCK10, PAPD5, HOXA9, and
CASP8AP2) remained constant at least until the third month
of follow-up (Additional Table 3). The determination of
cutoff values and B-ALL diagnosis capacity for IL10,WNT5A,
OPAL1, CCND2, and CASP8AP genes was determined
(Figure 1) considering their marked differences with respect
to the controls (𝑃 values ≤ 0.001). The ranges of values
obtained for the area under the curve (AUC) and cutoff
values for these genes were of 0.8673 to 0.953 and 4.015
to 44.79, respectively. WNT5A has been showed to be the
best parameter in the ROC analysis. Considering 44.79 as
normalizedΔCq cutoff value forWNT5A, theAUCcurvewas
calculated to be 0.953, with a sensitivity of 0.863, a specificity
of 1, positive predictive value (PPV) equal to 1, and a negative
predictive value (NPV) of 0.41.
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Figure 1: Gene expression classifier for B-ALL diagnosis. ROC curves show the independent accuracy of the 5-probe-set classifier B-ALL
diagnosis. (a) ROC curve for IL10, (b) ROC curve for WNT5A, (c) ROC curve for OPAL1, (d) ROC curve for CCND2, and (e) CASP8AP2
ROC curve, respectively.
Expression levels for the genes that showedΔCq statistical
differences at least one time between study groups were
determined using healthy controls as calibrator (Additional
Table 4). Additional Table 4 shows the descriptive statistics of
expression level for 30 genes evaluated. In general, ΔCq dif-
ferences observed between groups for IL10,WNT5A, OPAL1,
CCND2, and CASP8AP genes reflected their overexpression
with respect to the controls and themedian of expression level
for each gene was 2.2, 5.4, 7.7, 6.2, and 6.6, for IL10, WNT5A,
OPAL1, CCND2, and CASP8AP, respectively.
The results of the identification of genes with statistical
differences in their level of expression through time are dis-
played in Table 2. Considering healthy controls as calibrator,
in B-ALL cases the expression levels of 23 genes showed
differences between the times evaluated (Table 2). Of these 23
genes, only the differences observed in the expression levels
of IL2RA, SORT1, DEFA1, and FLT3 genes in at least one
of the studied times were associated with relapse (Table 3).
Differences in the median of the FLT3 expression levels
between B-ALL cases that presented the event (relapse or
ALL-related death) and the event-free group were a constant
in the three times studied (𝑃 < 0.05). When classification of
the cohort by diagnosis time or by risk group was considered,
FLT3 expression difference between groups was observed
only at one month of starting treatment in children (𝑃 =
0.044) and standard risk (𝑃 = 0.008) subgroups, respectively.
In the same sense, differential expression of IL2RA gene
between groups (with/without event) was observed at B-ALL
diagnosis time for all the cases and in the children group
(𝑃 values < 0.05). DEFA1 expression presented differences at
time 3 for all the cases and in high risk patients (𝑃 values <
0.05). SORT1 differences were observed only at time 3 in the
adults group (𝑃 = 0.039).
To determine the association between expression of
IL2RA, SORT1, DEFA1, and FLT3 genes and B-ALL survival,
the expression level cutoff values in which the sum of
specificity and sensibility were the highest (nearest two) were
determined for each gene by ROC analysis. In this test, the B-
ALL cases were grouped as event-free patients and those that
presented the event (relapse/death). Calculated cutoff values
were used to construct and compare survival curves using
B-ALL patients whose expression level was above the cutoff
and B-ALL cases with expression levels equal to or below the
calculated cutoff. The results obtained are shown in Figure 2
and Table 4, respectively. There were statistical differences
between survival curves in the study groups (defined by
the cutoffs values) for all the genes and times evaluated (𝑃
values < 0.05); the exception was represented by the IL2RA
expression at B-ALL diagnosis time in children and DEFA1
at time 3 in the high risk subgroups, respectively (𝑃 values
> 0.05). The differences in survival times between groups
ranged from 6.13 (FLT3-T1) to 22.5 (FLT3-T2-standard risk)
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Table 2: Differences in gene expression levels through time in 73
B-ALL patients.
Gene
Times included in the comparison and significant
𝑃 values
Time 1/time 2 Time 1/time 3 Time 2/time 3
IL2RA 0.011 ns ns
IL10 0.012 ns ns
CD10 0.016 ns ns
CD3D 0.018 ns ns
HOXA9 0.041 ns ns
PAX5 0.006 ns ns
CTNNB ns 0.039 ns
GSK3B ns 0.003 ns
JAK2 ns 0.032 ns
FOS1 ns 0.007 ns
RAPGEF2 ns 0.044 ns
SORT1 ns 0.023 ns
HK2 ns 0.007 ns
PAX5 ns 0.002 ns
DEFA1 ns 0.011 ns
NOTCH1 ns 0.026 ns
S100A8 ns 0.002 ns
ns ns 0.037
BCL11A 0.023 ns ns
ns 0.012 ns
STAT5 0.017 ns ns
ns 0.012 ns
OPAL1 0.04 ns ns
ns 0.018 ns
FLT3 <0.001 ns ns
ns 0.009 ns
RXRA 0.01 ns ns
ns 0.002 ns
BCL2A
0.005 ns ns
ns <0.001 ns
ns ns 0.005
ns: nonsignificant, 𝑃 value >0.05.
months (Table 4). To identify the risk represented by these
differences, ORs were calculated preserving the same criteria
of classification groups (above or equal to/below cutoff
values). B-ALL patients with expression values for IL2RA,
SORT1, and FLT3 DEFA1 genes above cutoff values had
increased risk of relapse/death ranging from 3.73 to 27 times
compared to patients with expression values equal to or below
the cutoffs (𝑃 values < 0.05). FLT3 expression alone was able
to detect differences in survival times in a range of 6.13 to 11.8
months and increased relapse/death risk ranging from 3.73
to 6.05 at diagnosis time, at one month, and after twomonths
of starting treatment, respectively. Considering only the B-
ALL adults at time 3, an expression level of FLT3-T3 > −0.304
significantly increased the odds of the event relapse/death by
27.0 times (OR = 27; 95% CI: 2.0–368.4, 𝑃 = 0.013), being
the highest risk calculated from a specific gene in this study.
In this subgroup and at the mentioned cutoff, the observed
difference in survival times between groups was 13.43months
(𝑃 = 0.038). FLT3 expression was also associated with
survival in children at time 2 (𝑃 = 0.003) and in the standard
risk group after a month of starting treatment (𝑃 < 0.001).
Independently from FLT3 status, patients with an expression
level above 1.173 for IL2RA at B-ALL diagnosis time showed a
diminished survival time of 6.35 months (𝑃 = 0.012) and an
increased risk of 3.73 times (95% CI: 1.3–10.72; 𝑃 = 0.024) for
relapse/death among the studied population.
After 2 months of starting treatment and compared
to B-ALL cases with expression levels below or equal to
3.041, patients with expression level for DEFA1 > 3.041 had
increased odds of the event by 4.38 times (95% CI: 1.5–12.5;
𝑃 = 0.01). Finally, in adults at time 3, B-ALL cases with a
SORT1 expression level > 5.007 showed differences in their
survival curves when compared with cases with expression
level lower than or equal to the cutoff for this gene (𝑃 <
0.001); however, despite an increased risk of relapse/death
about 14 times for patients with SORT1 expression level above
5.007, their 𝑃 value reflected only a statistical trend (𝑃 =
0.05).
To evaluate the usefulness of IL2RA, SORT1, FLT3,
and DEFA1 expression as independent predictors of B-ALL
outcome a multivariate logistic regression using EFS/RFS as
dependent variable was carried out. In the statistical mod-
elling, WBC count, age, gender, age group (children/adult),
B-ALL immunophenotype, and SORT-T1, DEFA1-T1, FLT3-
T1-3, and IL2RA-T1 expression levels were included as inde-
pendent variables. The significant B-ALL outcome predictors
wereWBC count (𝑃 = 0.023), immunophenotype (OR = 2.6,
95% CI = 1.4–5.1, 𝑃 = 0.004), DEFA1-T1 (OR = 6.1, 95% CI =
1.01–36.9, 𝑃 = 0.049), and FLT3-T2 (OR = 8.6, 95% CI = 1.1–
69.3, 𝑃 = 0.043), respectively.
With the aim to test if clinical data including differences
in the counts of leukemic blasts cells recovered across samples
had an impact on the expression levels of genes associated
with survival, a correlation analysis was performed. In this
analysis age, B-ALL diagnosis WBC counts, and diagnosis
blasts data of 31 participants were included and their cor-
relations with FLT3-T1, SORT-T1, and DEFA1-T1 expression
levels were evaluated. Significant correlations between age,
WBC, and counts of blasts cells with FLT3-T1, SORT-T1, or
DEFA1-T1 expression levels were not observed (𝑃 values >
0.05). Positive correlation between the following pairs of
variables was identified: FLT3-T1/FLT3-T2 (𝑟 = 0.41, 𝑃 =
0.023), FLT3-T2/FLT3-T3 (𝑟 = 0.57, 𝑃 = 9.9 × 10−4), FLT3-
T1/IL2RA-T1 (𝑟 = 0.69,𝑃 = 1.1×10−5), and IL2RA-T1/DEFA-
T1 (𝑟 = 0.72, 𝑃 = 0.008), respectively.
4. Discussion
Whilst gene expression profiling studies in ALL have iden-
tified gene expression signatures associated with recurrent
cytogenetic abnormalities and in vitro drug responsiveness,
few studies have reported and validated gene expression
classifiers of survival [12]. In this study, gene expression
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Table 3: Positive associations between gene expression level and relapse/death.
Classification of
study population Gene
Time 1 Time 2 Time 3
Event- free
group
Event
group 𝑃 value
Event-free
group
Event
group 𝑃 value
Event- free
group
Event
group 𝑃 value
All the ALL cases
FLT3 −0.049 0.434 0.022∗ −0.598 −0.075 0.028∗ −0.242 0.023 0.02∗
IL2RA 1.164 1.493 0.038∗ — — — — — —
DEFA1 — — — — — — 1.99 4.012 0.01∗
Children FLT3 — — — −0.602 0.025 0.044
∗ — — —
IL2RA 1.193 1.558 0.038∗ — — — — — —
Adults FLT3 — — — — — — −0.49 0.03 0.046
∗
SORT1 — — — — — — 3.84 5.34 0.039∗
Standard risk FLT3 — — — −0.707 −0.025 0.008∗ — — —
High risk DEFA1 — — — — — — 2.33 4.62 0.018∗
∗Statistically significant.
biomarkers of relapse-free survival were derived from the
gene expression profiles at three different time points on
samples of 73 patients with B-ALL (55 children and 18 adults).
We evaluated a 45-probe-set containing unique genes related
with the principal altered cell signaling pathways in leukemia
according to data bases (GeneCards, NCBI, etc.).
Normalized ΔCq values for 19 genes showed consistent
differences between cases and controls at least until the sec-
ond month of follow-up. Interestingly, observed differences
were independent of the treatment given. IL10, WNT5A,
OPAL1, CCND2, and CASP8AP2 normalized ΔCq presented
the most marked differences with respect to the controls;
WNT5A was the gene with the best sensitivity/specificity
trade-off and therefore the best potential B-ALL diagnosis
biomarker evaluated in this study.These findings are relevant
because this set of 23 genes may be considered as a B-ALL
related signature and their unknown role in the leukemogen-
esis process should be addressed in future studies. Compared
to controls, normalized ΔCq differences of IL10, WNT5A,
OPAL1, CCND2, and CASP8AP2 between the study groups
were translated in an overexpression of these genes; a high
expression of IL10, OPAL1, and CCND2 has been previously
reported [24–28]. Contrary to our findings using PBMC
samples under expression of CASP8AP2 and WNT5A genes
was previously reported in bone marrow specimens from B-
ALL cases [29, 30]. This discordance might be related to the
different origin of the biological samples evaluated in the
studies (PBMC or bone marrow).
Comparisons of gene expression levels through time in B-
ALL patients showed consistent differences among a set of 23
genes at least at two of the three time points evaluated and the
differences in the expression levels of IL2RA, SORT1, DEFA1,
and FLT3 genes in at least one of the times studied were
associated with relapse and/or B-ALL-related death. Interest-
ingly, the overexpression of FLT3 at B-ALL diagnosis and at
one and two months after starting treatment was associated
with relapse/death in our study group; these findings were
established without regard to subclassification by clinical
characteristics and were significant in children (time 2),
adults (time 3), and standard risk (time 2) subgroups. IL2RA
overexpression at the time of B-ALL diagnosis was significant
in the children’s group. In the same sense, while DEFA1
overexpression was significant for all B-ALL cases (time 3)
and in the high risk subgroup (time 3), SORT1 overexpression
was only different in adults (time 3). Previous results indicate
that differences through time in specific gene expression
profiles may be useful to identify genes with capacity to
pinpoint B-ALL cases with a higher potential risk to relapse.
Grouping the B-ALL cases as event-free patients and
those that presented the event (relapse/death), we calculated
level expression cutoff values for IL2RA, SORT1, DEFA1,
and FLT3 by ROC analysis. These cutoff values allowed us
to construct and compare survival curves (and calculate
their respective ORs) for groups of B-ALL patients whose
expression level was above the calculated cutoff and for
patients with gene expression levels equal to or below their
respective cutoff. In our study patients with expression values
for IL2RA, SORT1, FLT3, and DEFA1 genes above the cutoff
values have an increased risk of relapse/death ranging from
3.73 to 27 times compared to B-ALL patients with expression
values equal to or below these cutoffs (𝑃 values < 0.05). The
usefulness of FLT3 gene expression to predict an increased
risk of relapse/death was more evident than for other genes;
since taking into account their cutoffs, this gene was able to
identify differences in survival times in a range of 6 to 22
months, and increased relapse/death risks ranging from 3.73
to 27 times. For example, in adults at 2 months after starting
treatment the highest risk was observed for patients with
an expression level of FLT3-T3 > −0.3036, which presented
a decreased mean of survival time of 13.43 months and
increased odds of the event (relapse/death) by 27 times (OR =
27; 95% CI: 2.0–368.4, 𝑃 = 0.013). This trend of FLT3
results was valid for B-ALL cases without subclassification
at any studied time and after a month of having started the
treatment for children and high risk subgroups, respectively.
FLT3 gene is a class III receptor tyrosine kinase involved in
signaling pathways regulating the proliferation of pluripotent
stem cells, early progenitor cells, and immature lymphocytes.
Aberrantly expressed FLT3 has been observed at high levels
in a spectrum of hematologic malignancies, including 70%
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Figure 2: Continued.
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Figure 2: Log-Rank Survival Test. The comparison between survival curves according to specific cutoff values for genes differentially
expressed in relapse/death versus event-free cases is showed without classification for (a) FLT3 time 1, (b) IL2RA time 1, (c) FLT3 time 2,
(d) FLT3 time 3, and (e) DEFA1 time 3, respectively. Considering B-ALL subgroups, figure shows in children (f) IL2RA time 1 and (g) FLT3
time 2, respectively, and in adults (h) FLT3 time 3 and (i) SORT1 time 3. In mild risk (j) FLT3 time 2 and finally survival curve for (k) DEFA1
time 3 in high risk subgroup, respectively.
to 100% of AML, B-ALL, a fraction of T-Cell ALL, and CML
in lymphoid blast crisis [31]; however, this is the first report
that evaluated its potential role and association to B-ALL
prognosis.These results suggest that the constant monitoring
of FLT3 expression profile might lead to a better monitoring
in relation to the therapy protocol.
It is important to mention that in this study the presence
of BCR-ABL rearrangement was evaluated in the B-ALL
cases; only three patients (4.1%) were positive for this molec-
ular abnormality. Considering that the number of patients
with this translocation was low and that the screening
of other molecular abnormalities was not included in the
characterization of the cases, we decided not to remove them
from the analysis; however, despite this limitation, the results
obtained (without molecular abnormalities classification)
showed an important association with B-ALL prognosis, and
the expression of three genes demonstrated their usefulness
to identify risk of relapse/death of patients with B-ALL
(without incorporating additional clinical classification) and,
considering that abnormalities in chromosome number or
structure are present in 70–90% of the B-ALL cases [8–
10], it is possible that the prognosis associations observed
may be an independent factor of the presence of molecular
rearrangements. However, it is important to note that the
role of other no-BCR-ABL abnormalities on the expression
signatures of genes evaluated in this protocol represents a
significant issue to explore, and therefore its effect on the
prognosis value of these genes should be assessed.
We have shown that kinetics of early treatment response
evaluated by molecular methods from B-ALL diagnosis at
first and/or 2 months after starting the therapy are highly
associated with the prognosis of B-ALL patients. Clinical
application of these prognosis markers might allow the
prospective identification of a significant subgroup of ALL
patients with little chance for a cure if treated with contempo-
rary chemotherapeutic regimens, potentially indicating the
need for an early stem cell transplant or biologically tar-
geted treatment. Further analysis of these expression profiles
coupled with additional comprehensive genomic studies will
hopefully lead to the successful identification of novel thera-
peutic targets and more effective therapies for these patients.
5. Conclusions
The kinetics of early treatment response assessed by molec-
ular measures at one and two months after the beginning
of therapy is highly associated with leukemia prognosis.
Overexpression of FLT3 and DEFA1 genes retained indepen-
dent prognostic significance for B-ALL outcome, reflected as
increased risks of relapse/death among the study population.
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